June 1, 2024Journal of Clinical Oncology

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

View Full Paper

Ask AI

Bookmark

A selective CDK4 inhibitor combined with endocrine therapy showed manageable safety with no grade 4 or higher treatment-related adverse events across all cohorts.
Neutropenia occurred in 54.5% of dose-finding patients with 18.2% reaching grade 3, while relative dose intensity exceeded 98% across cohorts.
Phase 1/2a study evaluated PF-07220060 combined with letrozole or fulvestrant in 103 patients across CDK4/6 inhibitor-pretreated and treatment-naive settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 1/2a trial demonstrates favorable safety of PF-07220060 plus endocrine therapy in HR+/HER2- metastatic breast cancer, suggesting robust dose intensity.

Cite This Study

Giordano et al. (2024) studied this question.

synapsesocial.com/papers/68e66c68b6db6435875f797f https://doi.org/10.1200/jco.2024.42.16_suppl.3108

View Full Paper

Ask AI

Bookmark

Implication

Phase 1/2a trial demonstrates favorable safety of PF-07220060 plus endocrine therapy in HR+/HER2- metastatic breast cancer, suggesting robust dose intensity.

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

Key Points

Discussion

Implication

Cite This Study

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider